ACHE and Alzheimer disease: In mouse models of AD, myricetin administration (25 or 50 mg/kg, once daily, 6 days) can prevent scopolamine-induced increases in acetylcholinesterase (AChE) activities, thereby inducing significant increases in acetylcholine contents in the hippocampus (Wang et al., 2017; Figure 3 and Table 2), suggesting that reversing cholinergic hypofunction may be a key mechanism for the anti-AD’s effects of myricetin.